Jan Biotech is focused on developing nanotechnologies for molecular diagnostic assays of infectious diseases, particularly HIV. The company was founded based on a diagnostic platform that provides real-time quantitation of cell-based mRNA produced by latent HIV-infected cells. The platform can differentiate between cellular proviral and viral RNA in latent resevoirs of HIV-infected cells in HAART patients. The aim is to evaluate the development of the disease and monitor the success of antiviral treatments. The firm's intellectual properties include novel molecular in vitro assays for clinical diagnosis and quantification of latent infections such as HIV-1, as well as detection of aggressive cancer (ex., prostate) and cancer treatment monitoring
